Aktienanalyse zu Guardant Health Inc (GH)GHGuardant Health Inc

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Currently, Guardant Health Inc is not a good buy. The stock is trading at $158.60, which is below the average analyst price target of $200. Additionally, the RSI is at 29.76, indicating that the stock is oversold, but this could also suggest further downside risk. The recent insider selling has increased by 1274.28%, indicating a lack of confidence from those closest to the company. Furthermore, the stock has seen a 5-day change of -5.30% and a year-to-date change of +55.89%, suggesting volatility and potential profit-taking.

4 analysts cover GH: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 124.69.